Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Canaccord Genuitys 46th Annual Growth Conference on Tuesday, August 11, 2026 at 1:30pm Eastern Time (10:30am Pacific Time). The...

Breakthrough drugs, AI-powered technologies, and soaring global demand are driving one of healthcare’s fastest-growing markets   New York, NY – July 21, 2026 – Market News Updates News Commentary – Diabetes care is going through one of its biggest transformations in decades. Instead of simply helping patients keep their blood sugar under control, today’s therapies […] The post Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities appeared first on Financial News Media.

In trading on Thursday, the iShares U.S. Medical Devices ETF is outperforming other ETFs, up about 5% on the day. Components of that ETF showing particular strength include shares of Abbott Laboratories, up about 11.7% and shares of Tandem Diabetes Care, up about 8.2% on the da...

Tandem Diabetes targets diabetes market growth with a new reimbursement model and strong liquidity. Can it overcome macro and pump execution risks?

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ+TM automated insulin delivery (AID) technology is now compatible with Abbotts FreeStyle Libre 3 Plus continuous glucose monitoring...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at...

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.